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Abstract
Background: Advanced non-small cell lung cancer (NSCLC) patients often develop thromboembolic events,
including cerebral infarction (CI). However, the relationship between advanced NSCLC and CI has not been
thoroughly investigated. We examined the association between advanced NSCLC and CI and risk factors for CI in
advanced or post-operative recurrent NSCLC patients.
Methods: We retrospectively investigated 515 patients diagnosed with advanced or post-operative recurrent
NSCLC at Juntendo University Hospital between April 2009 and March 2014.
Results: Among the 515 patients evaluated, 15 patients (2.9 %) developed CI after diagnosis of advanced or post-
operative recurrent NSCLC. Univariate and multivariate analyses were conducted, and brain metastasis was the only
significant independent risk factor for CI (odds ratio 5.24, 95 % confidence interval 1.72–16.10, p = 0.004). The
incidence was 6.3 % in these patients. The median survival time was 36 days, and 1-year survival rate was 6.7 %
after development of CI. Overall survival from diagnosis of advanced NSCLC or post-operative recurrence was
significantly shorter in patients with CI than in patients without CI (223 days versus 895 days; HR, 3.46; 95 %
confidence interval, 2.04–6.02; p = 0.001).
Conclusions: The incidence of CI is high in advanced or post-operative recurrent NSCLC, and is especially higher in
patients with brain metastasis than in those without brain metastasis. Moreover, CI may affect patient’s prognosis.
Careful monitoring for the development of CI in patients with advanced or post-operative recurrent NSCLC is
needed, especially for patients with brain metastasis.
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Background
Cancer is the leading cause of death in the world. Non-
small cell lung cancer (NSCLC) is one of the most ag-
gressive diseases and has a poor prognosis compared
with other malignancies. NSCLC patients are usually di-
agnosed at an advanced stage and usually receive
chemotherapy. The prognosis of advanced NSCLC pa-
tients is improving due to the developments in chemo-
therapy, and better control of adverse events and
complications is becoming more important.
An association between cancer and thrombotic events
was first reported by Trousseau in 1865 [1]. The
association between cancer and thrombotic disease in-
cluding cerebral infarction (CI) is referred to as Trousseau
syndrome. Patients with solid tumors, including lung,
breast, ovary and pancreas cancers, have significantly
higher risk of thromboembolic complications than pa-
tients with hematologic malignancies such as leukemia
and malignant lymphoma [2]. In another report, the
prevalence of cancer was higher in stroke patients than in
the general population (p = 0.001). The most common
cancer types were colorectal cancer (20.2 %), prostate can-
cer (15.6 %), breast cancer (12.7 %), cancer of the urinary
tract system (10.3 %), gynecological cancer (6.2 %) and
lung cancer (4.5 %) [3].
CI impairs activities of daily living and performance
status (PS). Most patients with CI will not be able to* Correspondence: mtkatou@juntendo.ac.jp; tshukuya@juntendo.ac.jp1Department of Respiratory Medicine, Juntendo University Graduate School
of Medicine, 3-1-3, Hongo, Bunkyo-ku, Tokyo 113-8431, Japan
Full list of author information is available at the end of the article
© 2016 Kato et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kato et al. BMC Cancer  (2016) 16:203 
DOI 10.1186/s12885-016-2233-1
continue anticancer treatment. Therefore, the survival of
cancer patients with CI is poor.
Although some previous papers reported the incidence
of CI in lung cancer patients, the incidence rate was
based on data from a registry including all lung cancer
patients, from early stage to advanced stage [4, 5]. More-
over, the effect of CI on the prognosis of advanced
NSCLC patients has not been reported. The aim of this
study was to investigate the association between CI and
advanced or post-operative recurrent NSCLC, risk fac-
tors for CI in advanced NSCLC, and the effect of CI on
the prognosis of advanced NSCLC.
Methods
Study design
Between April 2009 and March 2014, 532 patients were
diagnosed with unresectable stage IIIA, IIIB, or IV or
post-operative recurrent NSCLC at the Juntendo Univer-
sity Hospital. Seventeen patients were transferred to other
hospitals immediately after diagnosis. A total of 515 pa-
tients attended our hospital and were enrolled in this case
control study. We divided all patients into two groups, pa-
tients with and without CI. Then, we evaluated the differ-
ences between the two groups in any items.
Data regarding the patients’ baseline characteristics at
the time of diagnosis of advanced NSCLC or post-
operative recurrence were retrospectively collected, in-
cluding age, sex, smoking history, Eastern Cooperative
Oncology Group (ECOG)-PS, histological type, clinical
stage, brain metastasis, and complications (hypertension,
diabetes, hyperlipidemia, atrial fibrillation and old myo-
cardial infarction).
CI was firstly detected by symptom and neurological
examination and confirmed by brain magnetic resonance
imaging (MRI) including diffusion-weighted MRI and
neurologist. Blood examinations, especially D-dimer
levels, were evaluated in patients with CI. For patients
with CI, the clinical course before and after CI and sur-
vival time from the onset of CI were evaluated. Overall
survival (OS) from diagnosis of advanced NSCLC or
post-operative recurrence after radical surgery or che-
moradio/radiotherapy was evaluated and compared be-
tween patients with CI and without CI.
All patients involved in this study provided verbal in-
formed consent for the use of their medical data. This
study protocol was approved by the Juntendo University
Ethical Committee and registered under number 26–635.
Statistical method
We used the chi square test, Fisher's exact test, or
Wilcoxon two-sample test to compare patient characteris-
tics. Univariate and multivariate analyses were performed
using logistic regression to assess the risk factors for CI.
OS was plotted using the Kaplan–Meier method.
Differences in OS were analyzed using the log-rank test,
and hazard ratio (HR) was calculated by cox proportional
hazard model. All p-values <0.05 were considered statisti-
cally significant. All statistical analyses were performed
using SPSS ver. 15.0 for Windows (Chicago, IL, USA).
Results
Incidence of CI and patient characteristics
Between April 2009 and March 2014, 532 patients were
diagnosed with advanced or post-operative recurrent
NSCLC. Seventeen patients were excluded from this re-
search because they were transferred to other hospitals
immediately after diagnosis. Thereafter, 515 patients
were enrolled in this case–control study (Fig. 1). Fifteen
out of 515 patients (2.9 %) developed CI after being di-
agnosed with advanced NSCLC or post-operative recur-
rence after radical surgery or chemoradio/radiotherapy.
The baseline characteristics of patients with and without
CI are listed in Table 1. There were no significant differ-
ences in age, sex, smoking history, ECOG-PS, disease
stage and tumor histology between the two categories.
Additionally, there were no significant differences in
hypertension, diabetes, hyperlipidemia, atrial fibrillation,
and old myocardial infarction between patients with and
without CI. More male patients developed CI, although
there was no significant difference (p = 0.11).
Cerebral infarction and risk factors
Patients who developed CI are listed in Table 2. Thirteen
patients was diagnosed with advanced NSCLC and 2 di-
agnosed with post-operative recurrence NSCLC. CI was
first detected by symptom and neurological examination,
and confirmed by a neurologist with brain MRI finding.
All patients had some symptoms at the onset of CI.
Twelve patients had hemiplegia, 10 had dysarthria, and
5 had disturbance of consciousness. Ten patients had
multiple CIs and 5 patients had a single CI on brain
MRI. Fourteen patients developed CI during anticancer
therapy, including radiation therapy (2 patients) and
Patients diagnosed with advanced and post-operative 
recurrent NSCLC at Juntendo university hospital between 
April 2009 and March 2014 (n = 532) 
without CI (n = 500)with CI (n = 15)
Patients with advanced and post-operative recurrent 
NSCLC attended to our hospital (n = 515) 
Excluded
Patients transferred
to other hospital before 
treatment (n = 17)
Fig. 1 Patients selection
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chemotherapy (12 patients). One patient was not able to
receive anticancer treatment because of advanced age
and dementia. In two patients who developed CI during
radiation therapy, one patient received only radiation
therapy before onset of CI, and the other patient had
been treated with carboplatin (CBDCA), pemetrexed
(PEM) plus epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI), gefitinib followed by ra-
diation therapy before onset of CI. Seven patients devel-
oped CI during first line chemotherapy. Of these
patients, 2 patients treated with CBDCA plus paclitaxel
(PTX), 2 received cisplatin (CDDP) plus PEM, and 1 was
treated with CBDCA plus PEM. There was no patient
treated with bevacizumab. Four patients developed CI
during second line chemotherapy. One patient was
treated with docetaxel monotherapy and the other re-
ceived PEM. Three patients with sensitive mutation of
EGFR and 1 with EML4/ALK fusion gene developed CI
during treatment with EGFR-TKI, erlotinib, and EML4/
ALK inhibitor, crizotinib, respectively. Only 1 patient
treated with erlotinib for first line treatment, and the other
2 patients treated for second line. One patient received
Table 1 Patients characteristics
Without CI N = 500 With CI N = 15 P
Age (year) Median (range) 66 (34–92) 64 (47–78) 0.39
Sex Male (%) 293 (58.6 %) 12 (80.0 %) 0.11
Smoking history Yes (%) 316 (63.2 %) 12 (80.0 %) 0.19
PS 0,1 (%) 484 (96.8 %) 14 (93.3 %) 0.42
Histology Adenocarcinoma (%) 411 (82.2 %) 12 (80.0 %) 0.66
Advanced (%) 381 (76.2 %) 12 (80.0 %) 0.97
Post-operative recurrence (%) 119 (23.8 %) 3 (20.0 %)
Hypertension Yes (%) 213 (42.6 %) 7 (46.7 %) 0.75
Diabetes Yes (%) 93 (18.1 %) 2 (13.3 %) 0.61
Old myocardial
infarction
Yes (%) 46 (9.2 %) 2 (13.3 %) 0.77
Hyperlipidemia Yes (%) 95 (18.7 %) 1 (6.7 %) 0.25
Atrial fibrillation Yes (%) 23 (4.5 %) 1 (6.7 %) 0.71
CI cerebral infarction, PS performance status
Table 2 Our cerebral infarction cases








D-dimer Outcome OS from
CI (days)
1 70s IV Ad – Multi + Erlotinib 2.2 Recover 791
2 50s rec Ad – Multi + DTX 5.6 Recover 341
3 60s IV Ad + Multi + CBDCA + PTX 4.9 Recover 280
4 60s IIIB Sq – Multi + CBDCA + PTX 4.6 Recover 161
5 70s IV Ad + Multi + Erlotinib 24.7 Recover 125
6 60s IV Sq + Mono + RTx 1.8 Dead 66
7 70s IV Ad + Multi – – 37.8 Recover 44
8 40s IV Ad + Multi + Erlotinib 10 Dead 36
9 50s IV Ad + Multi + Crizotinib 46 Dead 32
10 60s IV La + Multi + DTX 46.6 Dead 28
11 50s IV Ad + Mono + CDDP + PEM 2.8 Dead 25
12 60s rec Ad – Mono + CBDCA + PTX 60 Recover 17
13 70s IV Ad + Multi + RTx 22.3 Dead 7
14 70s IV Ad – Mono + PEM 141 Dead 1
15 50s rec Ad + Mono + CDDP + PEM 11.3 Dead 1
rec recurrence, Ad adenocarcinoma, Sq squamous cell carcinoma, DTX docetaxel, CBDCA carboplatin, PTX paclitaxel, CDDP cisplatin, PEM pemetrexed, RTx
radiation therapy
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crizotinib for first line treatment. Eleven patients had pro-
gressive disease for anticancer therapy at the onset of CI.
Carotid arteries were evaluated by ultrasonography in all
patients, and there was no evidence of thromboembolism.
Although 1 patient with CI had atrial fibrillation, he
received the anti-arrhythmic drug digitalis and the anti-
coagulant warfarin before the onset of CI. Serum D-dimer
level was also high in all patients at the onset of CI (average:
28.1, range: 1.8–141.5 μg/ml). Fourteen out of the 15 pa-
tients had to discontinue anticancer therapy.
The results of univariate and multivariate analyses to
identify risk factors for CI are shown in Tables 3 and 4.
Brain metastasis at diagnosis of advanced or post-
operative recurrent NSCLC was significantly associated
with CI on univariate analysis (odds rate [OR], 4.67;
95 % CI, 1.57–13.89; p = 0.006). Multivariate analysis
was performed using eleven variables (age, sex, smoking
history, ECOG-PS, histology, hypertension, diabetes,
hyperlipidemia, atrial fibrillation, old myocardial infarc-
tion and brain metastasis at diagnosis) and revealed that
only brain metastasis at diagnosis (OR, 5.24; 95 % CI,
1.72–16.10; p = 0.004) was a significant independent risk
factor for CI. The incidence of CI in patients with brain
metastasis was significantly higher than that in patients
without brain metastasis (6.3 vs. 1.4 %; p = 0.006). The
fatality rate was 60 % in patients with brain metastasis,
and 40 % in patients without brain metastasis; this differ-
ence was not statistically significant (Table 5). Among
the patients who developed symptomatic CI, 10 had mul-
tiple infarctions. Among the patients with brain metastasis
at diagnosis of advanced or postoperative recurrent
NSCLC, 7 had multiple micro CIs and 3 had a single large
Table 3 Univariate analysis of risk factors associated with
cerebral infarction
Overall without CI with CI OR 95 % CI P
Overall 515 500 15
Age 2.04 0.56–7.27 0.39
≦70 344 332 12
≧71 171 168 3
Sex 2.33 0.78–10.13 0.11
Female 210 207 3
Male 305 293 12
Smoking history 2.32 0.65–8.36 0.19
No 187 184 3
Yes 328 316 12
PS 2.16 0.26–17.48 0.42
0–1 498 484 14
2–3 17 16 1
Histology 0.71 0.16–3.20 0.66
Ad 423 411 12
Not Ad 92 89 3
Hypertension 1.18 0.42–3.32 0.75
No 295 287 8
Yes 220 213 7
Diabetes 0.67 0.15–3.03 0.61
No 420 407 13
Yes 95 93 2
Hyperlipidemia 0.31 0.04–2.34 0.25
No 419 405 14
Yes 96 95 1
OMI 1.49 0.33–6.78 0.77
No 467 454 13
Yes 48 46 2
Atrial fibrillation 1.48 0.18–11.75 0.71
No 491 477 14
Yes 24 23 1
Brain metastasis 4.67 1.57–13.89 0.006
No 355 350 5
Yes 160 150 10
PS performance status, Ad adenocarcinoma, OMI old myocardial infarction,
95 % CI 95 % confidential interval
Table 4 Multivariate analysis of risk factors associated with
cerebral infarction
Odds ratio 95 % CI P
Variable
Age (≦70 vs ≧71) 1.04 0.30–3.53 0.95
Sex (female vs male) 2.37 0.57–9.84 0.23
Smoking history (no vs yes) 2.69 0.50–14.53 0.25
PS (0–1vs 2–3) 2.19 0.23–20.12 0.49
Histology (Ad vs non-Ad) 0.60 0.12–2.85 0.53
Hypertension (no vs yes) 0.78 0.22–2.69 0.69
Diabetes (no vs yes) 1.46 0.33–6.34 0.57
Hyperlipidemia (no vs yes) 0.31 0.37–6.37 0.29
OMI (no vs yes) 0.70 0.08–6.07 0.75
Atrial fibrillation (no vs yes) 1.70 0.18–15.41 0.69
Brain metastasis (no vs yes) 5.24 1.72–16.10 0.004
PS performance status, Ad adenocarcinoma, OMI old myocardial infarction,
95 % CI 95 % confidential interval
Table 5 Incidence of CI and fatality rate
Total patients BM (−) BM (+)
Numbers 515 355 160
CI (+) 15 5 10
Incidence 2.9 % 1.4 % 6.3 %
Death 8 2 6
Fatality rate 53.3 % 40.0 % 60 %
CI cerebral infarction, BM brain metastasis
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CI. No statistically significant differences were observed
between brain metastasis and type of infarction.
Survival after CI and survival of patients with and without CI
Of the 15 patients who developed CI after diagnosis of
advanced or post-operative recurrent NSCLC, 8 patients
(53.3 %) died of CI. The median survival time (MST)
was 36 days, and 1-year survival rate was 6.7 % after de-
velopment of CI (Fig. 2). OS from diagnosis of advanced
NSCLC or post-operative recurrence was significantly
shorter in patients with CI than in patients without CI
(223 days versus 895 days; HR, 3.46; 95 % confidence
interval, 2.04–6.02; p = 0.001, Fig. 3).
Discussion
In this study, we found that the incidence of CI was
2.9 % in advanced or post-operative recurrent NSCLC,
and brain metastasis was the only risk factor for the de-
velopment of CI in patients with advanced or post-
operative recurrent NSCLC. In addition, the incidence
of CI in patients with brain metastasis was significantly
higher than that in patients without brain metastasis.
Few published studies have evaluated the association
between CI and advanced NSCLC. Population-based
data from Taiwan National Health Insurance revealed an
increased risk of CI in lung cancer patients [4]. In this
report, the incidence of CI in all the stages of lung can-
cer was 21.80 per 1000 person-years. Conversely, the
Dutch Pathology Registry linked to the PHARMO (Phar-
maco Morbidity) medical record linkage system did not
reveal increased risk of CI in lung cancer patients [5]. In
this report, the incidence of CI in all stages and histo-
logical types of lung cancer was 3.8 per 1000 person-
years in 6 months after diagnosis with lung cancer.
However, the incidence of CI in patients with advanced
or post-operative recurrent NSCLC has not been re-
ported yet. Two retrospective studies investigated the in-
cidence of and risk factors for thromboembolic events
including CI in lung cancer patients [6, 7]. However,
these reports included all stages and histological types of
lung cancer and did not focus on CI. The current study
is the first to evaluate the incidence of CI in advanced
NSCLC, and the risk factors for CI in advanced NSCLC
in terms of patient characteristics and complications.
An association between malignant neoplasms and
thromboembolism, including arterial thromboembolic
events and venous thromboembolism (VTE), has been re-
ported by several groups. It has been reported that 13.2 %
of newly diagnosed NSCLC patients have VTE [8]. In that
report, an increase in white blood cells was associated with
VTE. Another group reported that incidence of VTE was
higher among lung cancer patients with adenocarcinoma
histology than among those with squamous cell carcinoma
histology [9]. Thromboembolism may be associated with
poorly differentiated adenocarcinoma. Few case reports
have described an association between poorly differentiated
adenocarcinoma and thromboembolism in pancreatic,
breast, and advanced ovarian cancers [10–12]. In our study,
12 patients with CI had adenocarcinoma. However, there
were no significant differences in histology between patients
with CI and without CI. Further investigations with larger
study populations are warranted to determine whether
poorly differentiated adenocarcinoma is a risk factor for CI.
In general, CI was categorized as cardiac embolism,
atherosclerosis, and lacunar infarction. On the other
hand, it is difficult to easily classify etiology of CI in












Fig. 2 Survival time from development of cerebral infarction. Kaplan–Meier plot of survival time from diagnosis with cerebral infarction
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these patients. However, all of the patients with CI in
our study had a sudden onset of severe neurological
symptoms such as paralysis, dysarthria, and disturbance
of consciousness. Therefore, lacunar infarction could not
be an etiology of the CI in these patients. In our study,
10 patients had multiple infarctions and 5 patients had a
single infarction on brain MRI. In patients with multiple
infarctions, the CI must have been caused by thrombo-
embolism. Seven patients had hypertension, and 1 patient
had hyperlipidemia. In these patients, the occurrence of
atherosclerosis might be related to the CI, although the
development of thromboembolism/coagulation disorder is
also related to CI. Some papers discuss the causes of CI in
patients with cancer. One report described five causes of
CI: direct tumor relation, coagulation disorders, infection,
treatment related and paraneoplastic [13]. In terms of co-
agulation disorders, cancer is known as one of the ac-
quired prothrombotic states related to a high risk for
stroke [14]. Disseminated intravascular coagulation (DIC)
is usually associated with advanced cancer. In this case,
levels of specific markers for DIC, including D-dimer, are
often elevated. It has been reported that platinum
compounds are associated with a higher risk for stroke in-
cluding CI [15]. Circulating endothelial-derived and
platelet-derived microparticles occurring during the third
or fourth infusion might contribute to cisplatin-induced
stroke [16]. Other anticancer agents, including cyclophos-
phamide, 5-fluorouracil, paclitaxel, and methotrexate,
have been associated with the development of CI [13, 17,
18]. Whereas 5 patients received chemotherapy with
platinum agent (CDDP + PEM, CBDCA+ PEM, and
CBDCA + PTX), other patients were treated with PEM,
DTX, EGFR-TKI or crizotinib at the onset of CI. There-
fore, it is unclear that incidence of CI in patients treated
with platinum agent is higher than in patients received
non-platinum agent in this research. Most of the patients
developed CI during first or second line chemother-
apy. Because CI tends to occur immediately after
diagnosis with advanced or post-operative recurrent
NSCLC, attention should be paid if the patients have
the risk of CI.
Ten patients had multiple micro infarctions, and 5 had
single large infarctions on brain MRI. There was no evi-
dence of direct relation of tumor on brain MRI. How-
ever, taking into account the fact that the incidence of
CI in patients with brain metastasis was significantly
higher than that in patients without brain metastasis, in-
vasion or tumor emboli to vessels might cause CI. More-
over, cancer tissue releases the accelerator of coagulation
and cause prothrombotic states. When the patients have
brain metastases, accelerator of coagulation will increase
locally and elevate the risk of CI. To our knowledge,
there has been no report on the association between
brain metastasis from any cancer and CI. However, it
has been reported that the incidence ratio for subse-
quent ischemic stroke within 6 months after diagnosis in
patients with cancer of the nervous system is the highest
among all patients with any type of cancer [19]. This re-
port might support the findings of our study. There were
no cardiogenic embolisms by physical examination and
echocardiography, and the cause of CI in 10 patients










without CI median 895 days 95% CI 729.5-1060.5
with CI median 223 days 95% CI 120.7-325.3
Hazard ratio 3.46 (95% CI 2.04-6.02 p 0.01)
+ censored case
Follow up time (days)
Abbreviation: NSCLC non-small-cell lung cancer
Fig. 3 Overall survival from diagnosis of advanced or recurrent non-small cell lung cancer. Kaplan–Meier plot of overall survival for patients with
cerebral infarction and without cerebral infarction
Kato et al. BMC Cancer  (2016) 16:203 Page 6 of 7
coagulation disorders. CI developed during treatment in
14 out of 15 patients, and the cause of these CI could be
categorized as treatment related. Of these patients, 12
developed CI during chemotherapy. Cytotoxic agents
have been reported as risk factors for CI; however, 4 pa-
tients in our study experienced CI during treatment with
molecular targeted agents.
Only one patient with CI was able to receive antican-
cer therapy after development of CI. Median survival
time from onset of CI was 36 days. OS in patients with
CI was significantly shorter than that in those without
CI. These findings suggest that development of CI con-
tributed to a worse prognosis in patients with advanced
and recurrent NSCLC. Generally, the prognosis of ad-
vanced NSCLC patients is improving due to the devel-
opment of chemotherapy, and control of adverse events
and complications during chemotherapy, including CI, is
becoming more important. The prophylaxis of CI in ad-
vanced NSCLC during treatment should be examined in
future studies.
This analysis has several limitations. First, this was a
retrospective study. However, although we might miss
asymptomatic CI, the onset of CI is easy to detect, and
therefore its frequency might not differ significantly from
prospective evaluations. Moreover, asymptomatic CI is
not significant in clinical practice. Secondly, this study did
not include blood test findings in the analysis of risk fac-
tors for CI. However, although a study revealed an in-
creased white blood cell count associated with VTE, blood
test findings are not commonly known as risk factors for
CI, and we assessed hyperlipidemia as a risk factor.
Conclusions
This is the first study to evaluate the incidence of CI in ad-
vanced or post-operative recurrent NSCLC and the risk fac-
tors for CI in advanced or post-operative recurrent NSCLC
in terms of patient characteristics and complications. Our
findings suggest that the incidence of CI is high in advanced
or post-operative recurrent NSCLC, and especially higher in
patients with brain metastasis than in those without brain
metastasis. The prophylaxis of CI in advanced NSCLC dur-
ing treatment should be considered in future studies.
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